array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Tekla Life Sciences Investors" ["slug"]=> string(38) "30be8-us-tekla-life-sciences-investors" ["logo"]=> NULL ["description"]=> string(523) "Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund that primarily invests in the life sciences industry. The fund aims to provide long-term capital appreciation through investments in companies in the life sciences industry with potential for above-average long-term growth. It focuses on smaller, emerging companies and may invest up to 40% of its assets in restricted securities of both public and private companies. The fund is traded on the New York Stock Exchange under the ticker HQL." ["address_street"]=> string(17) "2 Liberty Sq FL 9" ["address_place"]=> string(6) "Boston" ["address_region"]=> string(13) "Massachusetts" ["founding_date"]=> string(10) "2000-01-26" ["website_domain"]=> string(12) "teklacap.com" ["website_url"]=> string(24) "https://www.teklacap.com" ["industry_codes"]=> array(1) { [0]=> string(39) "Management Investment Offices, Open-End" } ["employee_count"]=> int(7) ["article_count"]=> int(78) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(84) "Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Graham Capital Management L.P." ["snippet_en"]=> string(296) "Graham Capital Management L.P. raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 108.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 108,569 shares of the company's stock after acquiring a" ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-jnj-sec-filing-2023-11-30/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3002266e-8d28-47bf-a243-7dc9f574377a" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-11-30" ["categories"]=> array(8) { [0]=> string(11) "Acquisition" [1]=> string(12) "Stock Market" [2]=> string(14) "Issuing Shares" [3]=> string(18) "General Investment" [4]=> string(20) "Corporate Governance" [5]=> string(24) "Quarterly/Annual Figures" [6]=> string(16) "Share Repurchase" [7]=> string(31) "Financial Update/Profit Warning" } } [1]=> array(7) { ["title_en"]=> string(72) "Tekla Capital Management LLC Announces Closing of Transaction With abrdn" ["snippet_en"]=> string(300) "BOSTON–(BUSINESS WIRE)–HQH, HQL, THQ, THW Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manager to four NYSE listed healthcare and biotech thematic" ["url"]=> string(101) "https://www.fintechnews.org/tekla-capital-management-llc-announces-closing-of-transaction-with-abrdn/" ["image_url"]=> NULL ["source"]=> string(15) "fintechnews.org" ["publication_date"]=> string(10) "2023-10-29" ["categories"]=> array(5) { [0]=> string(11) "Acquisition" [1]=> string(22) "Business Restructuring" [2]=> string(25) "Business Model Resilience" [3]=> string(10) "Divestment" [4]=> string(20) "Business Development" } } [2]=> array(7) { ["title_en"]=> string(72) "Johnson & Johnson (NYSE:JNJ) Shares Bought by RNC Capital Management LLC" ["snippet_en"]=> string(217) "RNC Capital Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)." ["url"]=> string(112) "https://www.defenseworld.net/2023/10/09/johnson-johnson-nysejnj-shares-bought-by-rnc-capital-management-llc.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/541f0636-9fd8-491d-8e1a-8da06ab1b9dc" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-10-09" ["categories"]=> array(9) { [0]=> string(11) "Acquisition" [1]=> string(12) "Stock Market" [2]=> string(14) "Issuing Shares" [3]=> string(18) "General Investment" [4]=> string(18) "Expansion & Growth" [5]=> string(11) "Regulations" [6]=> string(24) "Quarterly/Annual Figures" [7]=> string(16) "Share Repurchase" [8]=> string(31) "Financial Update/Profit Warning" } } [3]=> array(7) { ["title_en"]=> string(47) "Tekla Life Sciences Investors Paid Distribution" ["snippet_en"]=> string(47) "Tekla Life Sciences Investors Paid Distribution" ["url"]=> string(53) "https://www.tmcnet.com/usubmit/2023/09/29/9890242.htm" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1b793880-7aad-4194-850e-8657ae430324" ["source"]=> string(10) "tmcnet.com" ["publication_date"]=> string(10) "2023-09-29" ["categories"]=> array(1) { [0]=> string(23) "Supply Chain Management" } } [4]=> array(7) { ["title_en"]=> string(82) "Lbmc Investment Advisors LLC Acquires 1,287 Shares of Johnson & Johnson (NYSE:JNJ)" ["snippet_en"]=> string(300) "Lbmc Investment Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,294 shares of the company's stock after purchasing an additional 1,287 s" ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-jnj-sec-filing-2023-09-29/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/28564341-88d3-4b88-b2ed-9009ed96617e" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-09-29" ["categories"]=> array(10) { [0]=> string(11) "Acquisition" [1]=> string(12) "Stock Market" [2]=> string(24) "Stock Research & Ratings" [3]=> string(14) "Issuing Shares" [4]=> string(18) "General Investment" [5]=> string(11) "Regulations" [6]=> string(24) "Quarterly/Annual Figures" [7]=> string(19) "Investment Requests" [8]=> string(16) "Share Repurchase" [9]=> string(31) "Financial Update/Profit Warning" } } [5]=> array(7) { ["title_en"]=> string(47) "Tekla Life Sciences Investors Paid Distribution" ["snippet_en"]=> string(298) "BOSTON, September 29, 2023--On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter" ["url"]=> string(80) "https://finance.yahoo.com/news/tekla-life-sciences-investors-paid-143500127.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3ca016b0-1e3d-460f-a082-899125631904" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-09-29" ["categories"]=> array(0) { } } [6]=> array(7) { ["title_en"]=> string(90) "Insider Buying: President Daniel Omstead Acquires 12,000 Shares of Tekla Life Sciences ..." ["snippet_en"]=> string(160) "On September 20, 2023, President Daniel Omstead of Tekla Life Sciences Investors (NYSE:HQL) made a significant purchase of 12,000 shares of the company's stock." ["url"]=> string(85) "https://finance.yahoo.com/news/insider-buying-president-daniel-omstead-090129980.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c4a0c45d-f201-4981-be22-137183d32e53" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-09-21" ["categories"]=> array(4) { [0]=> string(16) "Share Repurchase" [1]=> string(11) "Acquisition" [2]=> string(14) "Issuing Shares" [3]=> string(12) "Stock Market" } } [7]=> array(7) { ["title_en"]=> string(110) "Tekla Funds Announce Adjournment of Special Meetings and Implore Shareholders to Vote Their Shares Immediately" ["snippet_en"]=> string(39) "BOSTON--(BUSINESS WIRE)--Sep 13, 2023--" ["url"]=> string(196) "https://www.bakersfield.com/ap/news/tekla-funds-announce-adjournment-of-special-meetings-and-implore-shareholders-to-vote-their-shares-immediately/article_5eca924b-6c73-58fd-a9d5-9423d5752c8f.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f87bd777-283d-4f98-b9de-1bc02cb2206a" ["source"]=> string(15) "bakersfield.com" ["publication_date"]=> string(10) "2023-09-13" ["categories"]=> array(2) { [0]=> string(21) "Shareholders Feedback" [1]=> string(14) "Issuing Shares" } } [8]=> array(7) { ["title_en"]=> string(59) "Tekla Life Sciences Investors (HQL) Declares $0.32 Dividend" ["snippet_en"]=> string(205) "Tekla Life Sciences Investors said on August 15, 2023 that its board of directors declared a regular quarterly dividend of $0.32 per share ($1.28 annualized). Previously, the company paid $0.32 per share." ["url"]=> string(91) "https://www.nasdaq.com/articles/tekla-life-sciences-investors-hql-declares-$0.32-dividend-0" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-08-24" ["categories"]=> array(1) { [0]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(22) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(16) } [1]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(6) } [2]=> array(2) { ["name"]=> string(10) "Tax Havens" ["count"]=> int(6) } [3]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(5) } [4]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(4) } [5]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(4) } [6]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(4) } [7]=> array(2) { ["name"]=> string(16) "Share Repurchase" ["count"]=> int(4) } [8]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(3) } [9]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [11]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(2) } [12]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(2) } [13]=> array(2) { ["name"]=> string(22) "Business Restructuring" ["count"]=> int(2) } [14]=> array(2) { ["name"]=> string(20) "Corporate Governance" ["count"]=> int(2) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(23) "Supply Chain Management" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(19) "Investment Requests" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(1) } } } 30be8-us-tekla-life-sciences-investors